Pharming Group N.V. (PHAR) Retained Earnings (2019 - 2024)

Pharming (PHAR) has disclosed Retained Earnings for 6 consecutive years, with -$209000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Retained Earnings rose 99.92% year-over-year to -$209000.0, compared with a TTM value of -$209000.0 through Dec 2024, up 99.92%, and an annual FY2024 reading of -$209000.0, up 99.92% over the prior year.
  • Retained Earnings was -$209000.0 for Q4 2024 at Pharming, up from -$265.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $3.4 million in Q4 2021 and bottomed at -$307.8 million in Q4 2020.
  • Average Retained Earnings over 5 years is -$115.7 million, with a median of -$8.7 million recorded in 2022.
  • The sharpest move saw Retained Earnings soared 101.1% in 2021, then tumbled 2936.08% in 2023.
  • Year by year, Retained Earnings stood at -$307.8 million in 2020, then skyrocketed by 101.1% to $3.4 million in 2021, then plummeted by 356.97% to -$8.7 million in 2022, then crashed by 2936.08% to -$265.3 million in 2023, then skyrocketed by 99.92% to -$209000.0 in 2024.
  • Business Quant data shows Retained Earnings for PHAR at -$209000.0 in Q4 2024, -$265.3 million in Q4 2023, and -$8.7 million in Q4 2022.